DiabetesDrugReport
Your INDEPENDENT source of news about diabetes drugs
 
Diabetic Drug Information
Oral Diabetes Drugs
Drugs for Diabetic Complications

 
 
Diabetes Drug Report -- Diabetes Drugs in Development
 

With the number of diabetics growing rapidly, pharmaceutical and biotech companies are racing to develop new drugs.

New drug classes include glucokinase activators, glycogen phosphorylase inhibitors, protein tyrosine phosphatase 1B inhibitors and further new approaches to control of type 2 diabetes.

Here are some of the drugs currently under development. With the exception of Galvus, and possibly Acomplia, most are years away from submission for regulatory approval.

 
Drug
 Developer
Method of Action
Galvus Novartis Second in the class of drugs called dipeptidyl peptidase IV, or DPP-4, inhibitors that work to enhance the body's own ability to lower blood sugar.
Acomplia Sanofi-Aventis A CB-1 receptor antagonist awaiting FDA approval for weight loss, Acomplia is currently in clinical trials for use helping type 2 diabetics improve glycemic control in combination with metformin or sulfonylurea.
THEORY: Glucokinase activators (GKA) enhance glucose-stimulated insulin release from pancreatic islet cells and glucose disposition by the liver, thus reducing blood glucose and reducing weight.
  Roche  
ID1101 Innodia  
     
THEORY: Gglycogen phosphorylase inhibitors (GPI) inhibit glycogenolysisis, thus reducing blood glucose.
  Pfizer  
  Sanofi-Aventis  
     
THEORY: Antagonizing the activity of fructose 1,6- bisphosphatase inhibit gluconeogenesiss, thus reducing blood glucose.
CS-917 Sankyo/Metabasis  
THEORY: Inhibition of Protein tyrosine phosphatase 1B (PTP-1B) prevents downregulation of the insulin receptor, thus improving insulin action.
113715 Isis  
     

 

 
Diabetes Resources
Privacy Policy | Terms and Disclaimers | About the Diabetes Drug Report
Contact Us
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.
This is an independent news site reporting on prescription and over-the-counter diabetes drugs and on the many additional diabetes drugs currently in various stages of development.. Nothing on this site is intended to infringe on any trademarks. Nothing on this site is intended as medical advice. The information provided is for informational purposes only. Always consult a doctor or medical professional with questions regarding a medical condition.

Last Updated: 07/29/2007 Copyright 2004-2006 Medical Week News, Inc. All Rights Reserved